Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Tvardi Therapeutics (TVRD) Shares Outstanding (Diluted Average) (2019 - 2025)

Tvardi Therapeutics' Shares Outstanding (Diluted Average) history spans 7 years, with the latest figure at $1.5 million for Q1 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 0.51% to $1.5 million in Q1 2025 year-over-year; TTM through Mar 2025 was $1.5 million, a 0.51% increase, with the full-year FY2024 number at $4.6 million, up 1.12% from a year prior.
  • Shares Outstanding (Diluted Average) hit $1.5 million in Q1 2025 for Tvardi Therapeutics, down from $4.6 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for TVRD hit a ceiling of $54.8 million in Q3 2024 and a floor of $1.5 million in Q1 2024.
  • Historically, Shares Outstanding (Diluted Average) has averaged $38.2 million across 5 years, with a median of $50.7 million in 2021.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): grew 7.19% in 2022 and later plummeted 97.19% in 2024.
  • Tracing TVRD's Shares Outstanding (Diluted Average) over 5 years: stood at $50.7 million in 2021, then tumbled by 91.18% to $4.5 million in 2022, then increased by 0.92% to $4.5 million in 2023, then grew by 1.12% to $4.6 million in 2024, then plummeted by 66.6% to $1.5 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for TVRD at $1.5 million in Q1 2025, $4.6 million in Q4 2024, and $54.8 million in Q3 2024.